Immuno (Mar 2022)

Host–Pathogen Interaction in Leishmaniasis: Immune Response and Vaccination Strategies

  • Hadida Yasmin,
  • Anureeta Adhikary,
  • Mohammed N. Al-Ahdal,
  • Syamal Roy,
  • Uday Kishore

DOI
https://doi.org/10.3390/immuno2010015
Journal volume & issue
Vol. 2, no. 1
pp. 218 – 254

Abstract

Read online

Leishmaniasis is a zoonotic and vector-borne infectious disease that is caused by the genus Leishmania belonging to the trypanosomatid family. The protozoan parasite has a digenetic life cycle involving a mammalian host and an insect vector. Leishmaniasisis is a worldwide public health problem falling under the neglected tropical disease category, with over 90 endemic countries, and approximately 1 million new cases and 20,000 deaths annually. Leishmania infection can progress toward the development of species–specific pathologic disorders, ranging in severity from self-healing cutaneous lesions to disseminating muco-cutaneous and fatal visceral manifestations. The severity and the outcome of leishmaniasis is determined by the parasite’s antigenic epitope characteristics, the vector physiology, and most importantly, the immune response and immune status of the host. This review examines the nature of host–pathogen interaction in leishmaniasis, innate and adaptive immune responses, and various strategies that have been employed for vaccine development.

Keywords